- Home
- ACON vs PRFX Comparison
ACON vs PRFX Comparison
Compare ACON & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | PRFX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACON | PRFX |
|---|---|---|
| Price | $2.48 | $2.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 96.5K | ★ 253.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.58 |
| 52 Week High | $21.31 | $3.71 |
Technical Indicators
Market Signals| Indicator | ACON | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 32.58 | 67.26 |
| Support Level | $2.34 | $1.03 |
| Resistance Level | $7.98 | $3.65 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 25.49 | 77.62 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.